Researchers found amyloid-β structural changes could identify patients who would develop Alzheimer's an average of eight years before a clinical diagnosis.
The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.
The MyCare Total Risperidone Assay Kit and MyCare Paliperidone Assay Kit can help guide physicians in their decision-making process by providing objective evidence of medication levels.
